Parmax Pharma Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1002724,
    "name": "Parmax Pharma",
    "stock_name": "Parmax Pharma",
    "full_name": "Parmax Pharma Ltd",
    "name_url": "stocks-analysis/parmax-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "36.00",
    "chg": 2.45,
    "chgp": "7.3%",
    "dir": 1,
    "prev_price": "33.55",
    "mcapval": "14.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540359,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE240T01014",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "1.27 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/parmax-pharma-1002724-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Parmax Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-parmax-pharma-fallingrising-3742565",
        "imagepath": "",
        "date": "2025-12-03 01:01:26",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Volatility</strong></p>\n<p>Despite opening the day with a positive gap of 2.01%, Parmax Pharma’s shares experienced significant volatility, trading within a wide intraday range of ₹3.97. The stock reached an intraday high of ₹34.98 but also touched a low of ₹31.01, reflecting a sharp 9.57% drop from the opening levels. This volatility was accompanied by a weighted average price skewed towards the lower end of the day’s range, indicating heavier trading volume near the lows. The stock has now declined for two consecutive sessions, losing 7.02% over this period, and underperformed its sector by 3.77% on the day.</p>\n<p>Technical indicators show the stock trading above its short-term moving averages (5-day, 20-day, and 50-day) but remaining below the longer-term 100-da..."
      },
      {
        "title": "Parmax Pharma Stock Falls to 52-Week Low of Rs.28 Amidst Weak Financials",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parmax-pharma-stock-falls-to-52-week-low-of-rs-28-amidst-weak-financials-3731354",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ParmaxPharma_priceRelatedfactors_3731354.png",
        "date": "2025-11-26 11:49:41",
        "description": "Parmax Pharma's shares touched a fresh 52-week low of Rs.28 today, marking a significant decline amid subdued financial performance and persistent volatility. The stock's intraday fall of 10.26% outpaced the Pharmaceuticals & Biotechnology sector, reflecting ongoing challenges within the company’s fundamentals."
      },
      {
        "title": "How has been the historical performance of Parmax Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-parmax-pharma-3713235",
        "imagepath": "",
        "date": "2025-11-18 23:02:10",
        "description": "Answer:\nThe historical performance of Parmax Pharma shows significant fluctuations in key financial metrics over the years.\n\nBreakdown:\nParmax Pharma's net sales have seen a notable increase from Mar'24 at 11.05 Cr to Mar'25 at 28.20 Cr, following a dip in Mar'23 at 15.42 Cr and Mar'22 at 18.25 Cr. However, the total expenditure also rose sharply to 27.95 Cr in Mar'25 from 14.43 Cr in Mar'24, leading to a slim operating profit of 0.25 Cr in Mar'25, a recovery from a loss of 3.38 Cr in the previous year. Despite this, the company reported a profit before tax of -2.40 Cr in Mar'25, an improvement from -5.66 Cr in Mar'24, but still indicative of ongoing challenges. The profit after tax also remained negative at -2.09 Cr in Mar'25, although less severe than the -5.75 Cr recorded in Mar'24. The company's reserves have turned negative, dropping to -6.44 Cr in Mar'25 from -4.35 Cr in Mar'24, reflecting a deteriora..."
      },
      {
        "title": "How has been the historical performance of Parmax Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-parmax-pharma-3703972",
        "imagepath": "",
        "date": "2025-11-15 00:20:37",
        "description": "Answer:\nThe historical performance of Parmax Pharma shows significant fluctuations in its financial metrics over the years.\n\nBreakdown:\nParmax Pharma's net sales have seen a notable increase from INR 11.05 crore in March 2024 to INR 28.20 crore in March 2025, following a decline from INR 15.42 crore in March 2023 and INR 18.25 crore in March 2022. The total operating income mirrored this trend, rising to INR 28.20 crore in March 2025 from INR 11.05 crore in March 2024. However, the company's total expenditure also increased, reaching INR 27.95 crore in March 2025, up from INR 14.43 crore in March 2024. This led to an operating profit of INR 0.25 crore in March 2025, a recovery from a loss of INR 3.38 crore in March 2024. Despite this, the profit before tax remained negative at INR -2.40 crore in March 2025, although it improved from INR -5.66 crore in March 2024. The profit after tax also showed a loss of I..."
      },
      {
        "title": "Why is Parmax Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-parmax-pharma-fallingrising-3681563",
        "imagepath": "",
        "date": "2025-11-07 23:59:24",
        "description": "As of 07-Nov, Parmax Pharma Ltd is experiencing a decline in its stock price, currently at 32.60, which reflects a decrease of 0.4 or 1.21%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total decline of 6.19% during this period. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. The delivery volume has also seen a significant drop, with a reported volume of 192 on 06 Nov, which is down by 88.57% compared to the 5-day average. The stock's performance over the past week shows a decline of 5.15%, while it has decreased by 26.33% year-to-date, indicating a persistent downward trend.\n\nIn the broader market context, the Sensex has shown a slight decline of 0.86% over the past week, which is less severe than Parmax Pharma's performance. While the benchmark has gained 1.57% over the last month and 6.50% year-t..."
      }
    ],
    "total": 109,
    "sid": "1002724",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/parmax-pharma-1002724"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "12-Jan-2026",
      "details": "RTA Certificate under regulation 74(5) of SEBI DP Regulations for quarter ended December 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "30-Dec-2025",
      "details": "Closure of trading window",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for The Board Meeting Was Initially Rescheduled On November 15 2025 And Thenafter On Today I.E. November 17 2025 Hence Board Has Approved The Unaudited Financial Statements For Quarter And Half Year Ended On September 30 2025",
      "datetime": "17-Nov-2025",
      "details": "The Board Meeting was initially rescheduled on November 15 2025 and thenafter on today i.e. November 17 2025 hence Board has approved the Unaudited Financial statements for quarter and half year ended on September 30 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Parmax Pharma falling/rising?

2025-12-03 01:01:26

Recent Price Movement and Volatility Despite opening the day with a positive gap of 2.01%, Parmax Pharma’s shares experienced significant volatility, trading within a wide intraday range of ₹3.97. The stock reached an intraday high of ₹34.98 but also touched a low of ₹31.01, reflecting a sharp 9.57% drop from the opening levels. This volatility was accompanied by a weighted average price skewed towards the lower end of the day’s range, indicating heavier trading volume near the lows. The stock has now declined for two consecutive sessions, losing 7.02% over this period, and underperformed its sector by 3.77% on the day. Technical indicators show the stock trading above its short-term moving averages (5-day, 20-day, and 50-day) but remaining below the longer-term 100-da...

Parmax Pharma Stock Falls to 52-Week Low of Rs.28 Amidst Weak Financials

2025-11-26 11:49:41

Parmax Pharma's shares touched a fresh 52-week low of Rs.28 today, marking a significant decline amid subdued financial performance and persistent volatility. The stock's intraday fall of 10.26% outpaced the Pharmaceuticals & Biotechnology sector, reflecting ongoing challenges within the company’s fundamentals.

How has been the historical performance of Parmax Pharma?

2025-11-18 23:02:10

Answer: The historical performance of Parmax Pharma shows significant fluctuations in key financial metrics over the years. Breakdown: Parmax Pharma's net sales have seen a notable increase from Mar'24 at 11.05 Cr to Mar'25 at 28.20 Cr, following a dip in Mar'23 at 15.42 Cr and Mar'22 at 18.25 Cr. However, the total expenditure also rose sharply to 27.95 Cr in Mar'25 from 14.43 Cr in Mar'24, leading to a slim operating profit of 0.25 Cr in Mar'25, a recovery from a loss of 3.38 Cr in the previous year. Despite this, the company reported a profit before tax of -2.40 Cr in Mar'25, an improvement from -5.66 Cr in Mar'24, but still indicative of ongoing challenges. The profit after tax also remained negative at -2.09 Cr in Mar'25, although less severe than the -5.75 Cr recorded in Mar'24. The company's reserves have turned negative, dropping to -6.44 Cr in Mar'25 from -4.35 Cr in Mar'24, reflecting a deteriora...

How has been the historical performance of Parmax Pharma?

2025-11-15 00:20:37

Answer: The historical performance of Parmax Pharma shows significant fluctuations in its financial metrics over the years. Breakdown: Parmax Pharma's net sales have seen a notable increase from INR 11.05 crore in March 2024 to INR 28.20 crore in March 2025, following a decline from INR 15.42 crore in March 2023 and INR 18.25 crore in March 2022. The total operating income mirrored this trend, rising to INR 28.20 crore in March 2025 from INR 11.05 crore in March 2024. However, the company's total expenditure also increased, reaching INR 27.95 crore in March 2025, up from INR 14.43 crore in March 2024. This led to an operating profit of INR 0.25 crore in March 2025, a recovery from a loss of INR 3.38 crore in March 2024. Despite this, the profit before tax remained negative at INR -2.40 crore in March 2025, although it improved from INR -5.66 crore in March 2024. The profit after tax also showed a loss of I...

Why is Parmax Pharma falling/rising?

2025-11-07 23:59:24

As of 07-Nov, Parmax Pharma Ltd is experiencing a decline in its stock price, currently at 32.60, which reflects a decrease of 0.4 or 1.21%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total decline of 6.19% during this period. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. The delivery volume has also seen a significant drop, with a reported volume of 192 on 06 Nov, which is down by 88.57% compared to the 5-day average. The stock's performance over the past week shows a decline of 5.15%, while it has decreased by 26.33% year-to-date, indicating a persistent downward trend. In the broader market context, the Sensex has shown a slight decline of 0.86% over the past week, which is less severe than Parmax Pharma's performance. While the benchmark has gained 1.57% over the last month and 6.50% year-t...

View All News